Q-Line Biotech Limited
Bookbuilding IPO · NSE
- Price band
- ₹326 - ₹343
- Lot size
- 400 shares
- Issue amount
- ₹214.48 cr
- Total subscription
- 102.49×
- Opens
- 21 May 2026
- Closes
- 25 May 2026
- Allotment
- 26 May 2026
- Listing
- 29 May 2026
Offer at a glance
Issue overview
- Issue size
- 62,53,200 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,30,400
- Fresh issue
- ₹214.48 cr
- Offer for sale
- ₹0 cr
- Registrar
- Purva Sharegistry India Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,37,200
- Issue type
- Bookbuilding IPO
- Shares before issue
- 1,70,74,999
- Shares after issue
- 2,33,28,199
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 800 | ₹2,74,400 |
| sHNI | 3 | 1,200 | ₹4,11,600 |
| bHNI | 8 | 3,200 | ₹10,97,600 |
Share reservation
Subscription & GMP
Subscription by category
Reported 25 May 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 197 |
| NIB | 0 | 49,781 |
| RETAIL | 2,599 | 1,85,677 |
| HNIs(10L +) | 495 | 31,162 |
| HNIs (2-10L) | 248 | 18,619 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 40.75 | 5,050.24 |
| FIIs | 0 | 711.11 |
| FIs | 0 | 1,107.77 |
| Mutual Funds | 0 | 94 |
| Others | 0 | 3,137.37 |
| RETAIL | 71.32 | 5,094.98 |
| HNIs 2+ | 10.19 | 829.29 |
| HNIs 10+ | 20.39 | 3,645.72 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 23.57 | 28.63 | 21.87 | 20.38 |
| ROE | 16.88 | 23.74 | 21.29 | 25.2 |
| ROCE | 13.32 | 17.66 | 19.25 | 22.14 |
| RONW | 0 | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 0 | 0 | 0 |
| POST IPO(PE) | 0 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Q-Line Biotech Limited is a healthcare diagnostics company engaged in the manufacturing and supply of In-Vitro Diagnostic (IVD) products, pathology reagents, rapid test kits, and laboratory equipment for hospitals, diagnostic laboratories, and healthcare institutions across India. Established in 2010, the company focuses on affordable diagnostic solutions and operates in the medical diagnostics and healthcare consumables segment, with its proposed IPO planned for listing on the NSE EMERGE SME platform.
Strengths
- Strong Manufacturing & R&D Capabilities: Focus on reverse engineering, innovation, and quality control supports product development.
- Diversified Diagnostic Product Portfolio: Wide range of reagents, kits, POC devices, and diagnostic equipment reduces dependency on one segment.
- Wide Distribution Network: Presence across all four regions in India ensures strong market reach and customer access.
Risk factors
- Regulatory Compliance Risk: Diagnostic and healthcare products are subject to strict approvals and quality standards.
- Dependence on Healthcare Sector Spending: Revenue linked to hospital, lab, and diagnostic industry demand.
- High Competition in IVD Market: Faces competition from established domestic and global diagnostic companies.
Promoters
Saurabh Garg
Amita Garg
Ayush Garg
Ajay Kumar Mahanty
Abhay Agrawal
Registrar & documents
Lead manager
Hem Securities Limited, Share India Capital Services Private Limited
Registrar & contacts
Purva Sharegistry India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station Lucknow, Uttar Pradesh, 226012
+91 5222435570
[email protected]Company website ↗Understanding QLINE IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.